WASHINGTON — The Trump administration announced a deal Thursday to expand access to popular obesity drugs made by Novo Nordisk and Eli Lilly — offering more coverage for Medicare and Medicaid beneficiaries and lowering the prices across the board. The administration argued that giving millions more people access to these drugs represents a major victory…
WASHINGTON — The Trump administration is nearing deals with Eli Lilly and Novo Nordisk to lower the prices of their weight loss drugs and expand access to them, people familiar with the talks told STAT. The companies have been close to a deal for weeks, one lobbyist with knowledge of the negotiations said, echoing others who…
Just over seven months after Eli Lilly launched Mounjaro (tirzepatide) in India, the diabetes and weight-loss medicine has emerged the country’s highest selling drug, racing past top-selling legacy drugs like antibiotic Augmentin. When Mounjaro debuted in March, the market was on the cusp of a transformation – driven by consumers showing greater willingness to use…
US pharma major Eli Lilly has tied up with Indian drug major Cipla to market and distribute a second brand of its breakthrough weight-loss and diabetes drug tirzepatide in India. The drug under the new brand name, Yurpeak, will be priced the same as the existing Mounjaro brand, which was launched in India in mid-March….
As far as Eli Lilly’s Dan Skovronsky is concerned, the revolving door can spin in a good direction. The drugmaker last week hired Peter Marks, a former top U.S. Food and Drug Administration official, and the move quickly sparked a fresh round of concern about conflicts of interest between the agency and industry, as well…
Roche gets USFDA clearance for Elecsys pTau181 test for Alzheimer’s disease We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data showing that it can improve blood glucose compared to a go-to therapy for type 2 diabetes. Topline results from the ACHIEVE-2 trial showed orforglipron at a dose of 12 mg was better than AstraZeneca’s…
Eli Lilly‘s experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage trials, the company said on Wednesday, as it seeks to widen its lead in the rapidly growing market for GLP-1 drugs. The oral drug, orforglipron, is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company’s blockbuster injection…
A blood test developed by Roche and Eli Lilly that could help diagnose patients with Alzheimer’s disease more quickly has been cleared for marketing in the US. The FDA has approved the Elecsys pTau181 test to assist in the initial assessment for Alzheimer’s disease and other causes of cognitive decline in people aged 55 and…
Rs 233 Crore in 6 Months: Mounjaro Becomes India’s Second-Biggest Drug by Sales We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link